Grey Matters Health Inc. is a Canadian healthcare company primarily focused on the establishment of a new national network of dedicated brain PET scanning clinics in the U.S. under the NovaScan Neuroimaging Clinics TM brand, for the early-stage detection of AD and other forms of dementia, as well as epilepsy, neuro-oncology, and movement disorders including Parkinson's disease.
Grey Matters Health is also the parent company of Algernon NeuroScience, a wholly owned subsidiary, that has been advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury recovery, and has a drug development program for Repirinast, a repurposed drug for CKD. The Company's chronic cough drug Ifenprodil, which works by stopping cough in the brain, was sold for USD $2M cash and a 20% equity position in Seyltx Inc., a private U.S. based drug development company that continues to advance research on the drug.
Grey Matters Health Inc. is a billboard sponsor of Streetwise Reports and paid a fee for this company profile page.
Please refer to the important disclosures below for additional details.
Grey Matters Health Inc. (GREY:CSE; AGNPF:OTCQB; AGW2:XFRA) is developing dedicated brain PET imaging clinics as new Alzheimer's treatments introduce follow-up scans and Medicare removes its once-per-lifetime restriction.
Grey Matters Health Inc. (GREY:CSE; AGNPF:OTCQB; AGW2:XFRA) is preparing to open its first dedicated brain PET imaging clinic as new Alzheimer's treatments drive demand for earlier, specialized imaging.
Technical Analyst Stewart Thomson reviews Grey Matters Health Inc. (GREY:CSE; AGNPF:OTCQB; AGW0:FRA) following its achievement of a major regulatory milestone.
Grey Matters Health Inc. advances first U.S. brain-dedicated PET clinic for Alzheimer's detection amid surging diagnostics demand. Learn the key facts for investors.
Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) received its first brain-dedicated PET scanning system for its flagship Florida NovaScan Neuroimaging Clinic, which the company said will be the first U.S. facility dedicated to brain-only PET imaging for Alzheimer's disease and other neurological conditions.
Grey Matters Health Inc. closes CA$1.25M financing to launch brain-specific PET clinics targeting the expanding Alzheimer's diagnostics market and early detection demand.
Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) closed an expanded US$1.25 million private placement and said proceeds will support its Alzheimer's disease program and planned first U.S. brain-specific neuroimaging clinic.
Grey Matters Health advances its Alzheimer's neuroimaging strategy with fresh financing and plans for the first U.S. brain-specific PET clinic, capitalizing on rising demand for early detection tools.
Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) closed the first CA$500,000 tranche of a financing that the company said will support its Alzheimer's disease program and planned U.S. brain-specific neuroimaging clinic.
Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) amended warrant terms tied to its CA$1 million private placement as it advances plans for a U.S. brain-specific neuroimaging clinic focused on Alzheimer's diagnostics.
Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) signed an LOI tied to a minimum of 200 brain PET scans for an Alzheimer's clinical trial while expanding its NovaScan neuroimaging strategy.
Algernon Health (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) plans to rebrand to Grey Matters Health Inc. while advancing its Alzheimer's diagnostic strategy and U.S. clinic rollout.
Healthcare company Algernon Health (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) rebrands and unveils plan to open brain-specific PET scanning clinics in North America to meet rising demand for Alzheimer's diagnostics. Read more to learn how this shift positions the company at the center of a growing medical need.
Canadian healthcare and clinical stage drug development company Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) updates the pricing and warrant terms for its previously announced non-brokered private placement. Read why one technical analyst thinks the stock is ready to break out.
Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) secures exclusive Alzheimer's clinic rights in Canada and key U.S. cities, positioning for a high-growth breakthrough. Learn how Algernon plans to launch cutting-edge clinics featuring PET scan technology and expand into a multibillion-dollar diagnostics market
Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) has acquired NoBrainer Imaging, unlocking Alzheimer's PET scan clinics in Florida, Los Angeles, five select U.S. cities, and Canada. Read more to explore the growth potential.
Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) subsidiary Algernon NeuroScience has appointed Dr. Sandor Nardai as Principal Investigator for its upcoming Phase 2a DMT stroke study. Find out how this trial could reshape stroke recovery research.
Clinical-stage pharmaceutical development company Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) announced the drug ifenprodil achieved a 93% reduction in median cough count in an acute guinea pig citric acid challenge study. Find out why one analyst says this stock is headed for a "major bull market."
Technical Analyst Clive Maund shares an extensive overview of Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) to explain why he believes it is a Strong Buy.
Clinical-stage pharmaceuticals firm Algernon Pharmaceuticals Inc. has been issued a U.S. patent for the treatment of three related diseases with its investigational drug repirinast.
Algernon Neuro has completed the third stage of its dosage trial for DMT as a treatment for traumatic brain injury. Read on to see how the company expects to take psychedelics into the mainstream.
Algernon Pharmaceuticals Inc. has received a U.S. patent for a ground-breaking new Non-Alcoholic Steatohepatitis (NASH) drug under investigation, and is developing another for refractory chronic cough (RCC). Click here to read how the company is repurposing these two treatments with drugs that have a known safety history.
Algernon Pharmaceuticals Inc. and its subsidiary Algernon NeuroScience have reached a new milestone in a clinical trial investigating the psychedelic drug DMT for the treatment of brain injuries. Click here to learn more about new applications for psychedelics.
Treating traumatic brain injury with alternative pharmaceuticals is delicate work. Now one Canadian firm has enlisted the help of former National Football League Neurological Player Care Safety Director Dr. David Brody.
Technical analyst Clive Maund reviews Algernon Pharmaceuticals Inc.'s 6-month, 3-year, and 9-year charts to tell you whether you should be interested in this pharma company.
Clinical-stage Algernon Pharmaceuticals' multiple pipelines include testing a psychedelic for the treatment of stroke, and testing other drugs for idiopathic pulmonary fibrosis and chronic kidney disease.
Algernon Pharmaceuticals has entered into a clinical trial agreement with Yale and caught expert Clive Maund's attention. In light of this, Maund reviews the company's chart to tell you when he believes you should buy it.
Expert Clive Maund reviews the 6-month and 15-month charts for Awakn Life Sciences Corp. to explain why he thinks this company's technical setup is exceptionally positive.
One small-cap pharma co. just published more good news on a possible treatment for patients suffering from idiopathic pulmonary fibrosis, a lung disease that's usually terminal. Find out why the company has more near-term catalysts and may continue to build on an 84% gain since a private placement in mid-August.
Expert Chris Temple gives his view on Algernon Pharmaceuticals stock in light of its positive results for its Phase 2a study for the treatment of idiopathic pulmonary fibrosis and chronic cough.
A Canadian hedge fund doubled its stake in a tiny biotech that demonstrated promising results in a study that used a former Sanofi drug called Ifenprodil to treat idiopathic pulmonary fibrosis and chronic cough. Find out the name of the company and why one analyst has given it a 12-month CA$25 target price — a 560% increase from the unit price in its recent placement.
After Algernon Pharmaceuticals Inc.'s Ifenprodil treatment for chronic cough was reviewed in a Phase 2 analysis, analysts at Research Capital Corp. noted that it is maintaining its Speculative Buy rating on the company.
A scientist at a junior biotech company recently conducted an additional review of the top line data from a Phase 2a study that used NP-120 to treat idiopathic pulmonary fibrosis (IPF) and chronic cough — only to learn that it treated chronic cough far better than first thought.
Vancouver-based pharmaceutical development firm Algernon Pharmaceuticals Inc. recently reported topline data from a Phase 2a trial of ifenprodil in IPF patients with chronic cough that met its endpoint and demonstrated promising initial efficacy. Research Capital Corp. advised that it is maintaining its CA$25.00/share price target and "Speculative Buy" rating on the company.
One junior biotech company that attempts to treat current health problems with older previously approved drugs, recently completed a Phase 2 study that showed promise in the treatment of idiopathic pulmonary fibrosis (IPF) and chronic cough. It moved the small company a step closer to bringing the treatment to market.
A Vancouver-based tech startup decides to protect its shareholders versus following through on an acquisition that would have ultimately created company-threatening dilution.
In the Feb. 10 episode of Streetwise Live!, Host Cyndi Edwards interviews two medical experts who discuss the need for a new stroke treatment, explain why today's stroke treatments are so limited and express their excitement around what Algernon Pharmaceuticals is testing with DMT.
AlphaNorth Asset Management was recently recognized as the Number One equity hedge fund in Canada at the 2021 Alternative IQ Canadian Hedge Fund Awards due to its 5-year average investment return of 40.35%. Streetwise Reports sat down with the firm's co-Founder Steven Palmer to discuss some of the firm's recent investments and emerging opportunities for 2022.
Algernon Pharmaceuticals plans to be the world's first company to test the psychedelic drug DMT in stroke patients, and it's close to achieving its goal.
Drug re-purposing co. Algernon Pharmaceuticals Inc. is actively reinventing itself. The firm's leading therapeutic candidate NP-120 (Ifenprodil) is currently being evaluated in a Phase 2 trial for IPF and chronic cough, and the company is now moving forward with a revolutionary new use for DMT to treat ischemic stroke.
During Streetwise Live! on Jan. 27, 2022, representatives of Algernon Pharmaceuticals discussed the use of the psychedelic DMT in stroke sufferers. On the broadcast were Algernon CEO Christopher Moreau and consultants to the firm, Dr. David Nutt and Dr. Rick Strassman.
Algernon Pharmaceuticals Inc. has included novel salt forms of a psychedelic drug being investigated to combat strokes in its intellectual property applications.
Algernon Pharmaceuticals is a clinical-stage, small biotech that boasts a massive pipeline of lower risk and efficient drugs. Catalysts abound with this genius repurposing company.
Canadian company Algernon Pharmaceuticals Inc. has applied to uplist to the Nasdaq in hopes of attracting U.S. investors to its mission to repurpose drugs.
9/23/2026 – Grey Matters Announces the Closing of its Equity and Convertible Debenture Private Placement totalling CAD $1.12 Million
9/16/2026 – Grey Matters Announces an Increase to its Equity and Convertible Debenture Private Placement to CAD $1.1 Million
9/10/2026 – Grey Matters Closes First Tranche of $600,000 of its Equity and Convertible Debenture Private Placement
Important Disclosures
Grey Matters Health Inc. is a Billboard advertiser of Streetwise Reports and pays a flat fee. Fees fund both sponsor-specific activities and general report activities. Sponsor-specific activities may include aggregating content and publishing that content on the Streetwise Reports site, creating and maintaining company landing pages, interviewing key management, posting a banner/billboard, and/or issuing press releases.
The fees also cover the costs for Streetwise Reports to publish and syndicate investment opinion and comments, and also to curate or create sector-specific content.
Billboard advertising monthly fees range from $3,000 to $5,000.
This landing page contains a summary of the company that was prepared by that company.
Some landing pages contain investing highlights and a catalyst calendar that are prepared by that company.
The Expert Comments and Experts Following This Company sections of the landing page are compiled by Streetwise Reports.
There may be other information about the company that is not placed on the landing page, and Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on the landing page.
Readers should conduct their own research for all information publicly available concerning the company.
This landing page may be considered advertising for the purposes of 18 U.S.C. 1734.